RÉSUMÉ
CONTEXT: Mechanisms underlying pituitary corticotroph adenoma adrenocorticotropin (ACTH) production are poorly understood, yet circulating ACTH levels closely correlate with adenoma phenotype and clinical outcomes. OBJECTIVE: We characterized the 5' ends of proopiomelanocortin (POMC) gene transcripts, which encode the precursor polypeptide for ACTH, in order to investigate additional regulatory mechanisms of POMC gene transcription and ACTH production. METHODS: We examined 11 normal human pituitary tissues, 32 ACTH-secreting tumors, as well as 6 silent corticotroph adenomas (SCAs) that immunostain for but do not secrete ACTH. RESULTS: We identified a novel regulatory region located near the intron 2/exon 3 junction in the human POMC gene, which functions as a second promoter and an enhancer. In vitro experiments demonstrated that CREB binds the second promoter and regulates its transcriptional activity. The second promoter is highly methylated in SCAs, partially demethylated in normal pituitary tissue, and highly demethylated in pituitary and ectopic ACTH-secreting tumors. In contrast, the first promoter is demethylated in all POMC-expressing cells and is highly demethylated only in pituitary ACTH-secreting tumors harboring the ubiquitin-specific protease 8 (USP8) mutation. Demethylation patterns of the second promoter correlate with clinical phenotypes of Cushing disease. CONCLUSION: We identified a second POMC promoter regulated by methylation status in ACTH-secreting pituitary tumors. Our findings open new avenues for elucidating subcellular regulation of the hypothalamic-pituitary-adrenal axis and suggest the second POMC promoter may be a target for therapeutic intervention to suppress excess ACTH production.
Sujet(s)
Hypersécrétion hypophysaire d'ACTH/génétique , Pro-opiomélanocortine/génétique , Régions promotrices (génétique)/génétique , Adénome à ACTH/sang , Adénomes/métabolisme , Adolescent , Hormone corticotrope/sang , Hormone corticotrope/génétique , Adulte , Sujet âgé , Protéine de liaison à l'élément de réponse à l'AMP cyclique/sang , Exons , Femelle , Régulation de l'expression des gènes , Humains , Axe hypothalamohypophysaire/physiopathologie , Mâle , Tumeurs de l'hypophyse/métabolisme , Axe hypophyso-surrénalien/physiopathologie , Résultat thérapeutique , Jeune adulteRÉSUMÉ
Because an acidic cellular microenvironment is engendered by inflammation and may determine cell differentiation, we elucidated the impact of acidic conditions on induction of proopiomelanocortin (POMC) expression. Here, we demonstrate mechanisms for proton sensitivity of CRH receptor 1 (CRHR1) signaling to POMC and ACTH production. Low pH (6.8) resulted in doubling of POMC expression and ACTH production in pituitary cell line AtT-20 and in primary mouse pituitary cells. Using CRISPR knockout, we show that CRHR1 is necessary for acid-induced POMC expression, and this induction is mediated by CRHR1 histidine residues and calmodulin-dependent protein kinase II in both pituitary corticotroph cells and in nonpituitary cell lines expressing ectopic ACTH. In contrast, CRH ligand binding affinity to CRHR1 was decreased with acidic pH, implying that proton-induced POMC expression prevails in acidic conditions independently of CRH ligand binding. The results indicate that proton-induced CRHR1 signaling regulates ACTH production in response to an acidic microenvironment.
Sujet(s)
Pro-opiomélanocortine/métabolisme , Récepteur CRH/métabolisme , Hormone corticotrope/métabolisme , Séquence d'acides aminés , Animaux , Calcium-Calmodulin-Dependent Protein Kinase Type 2/métabolisme , Cellules HeLa , Humains , Concentration en ions d'hydrogène , Cellules MCF-7 , Mâle , Souris , Souris de lignée C57BL , Récepteur CRH/génétiqueRÉSUMÉ
The epidermal growth factor receptor (EGFR), expressed in adrenocorticotrophic hormone (ACTH)-secreting pituitary adenomas causing Cushing disease, regulates ACTH production and corticotroph proliferation. To elucidate the utility of EGFR as a therapeutic target for Cushing disease, we generated transgenic (Tg) mice with corticotroph-specific human EGFR expression (corti-EGFR-Tg) using a newly constructed corticotroph-specific promoter. Pituitary-specific EGFR expression was observed by 2.5 months, and aggressive ACTH-secreting pituitary adenomas with features of Crooke's cells developed by 8 months with 65% penetrance observed. Features consistent with the Cushing phenotype included elevated plasma ACTH and corticosterone levels, increased body weight, glucose intolerance, and enlarged adrenal cortex. Gefitinib, an EGFR tyrosine kinase inhibitor, suppressed tumor POMC expression and downstream EGFR tumor signaling, and ACTH and corticosterone levels were attenuated by 80% and 78%, respectively. Both E2F1 and phosphorylated Ser-337 E2F1 were increased in corti-EGFR-Tg mice and also colocalized with human POMC (hPOMC) in human pituitary corticotroph tumor samples. EGFR inhibition reversed E2F1 activity in vivo, whereas E2F1 inhibition suppressed POMC and ACTH in cultured human pituitary tumor cells. The corti-EGFR-Tg phenotype recapitulates ACTH-secreting pituitary adenomas and Cushing disease, validating the relevance of EGFR to corticotroph tumorigenesis. E2F1 is identified as a promising corticotroph-specific target for ACTH-dependent Cushing disease.
RÉSUMÉ
The transcription factor FOXP3 plays key roles in the development and function of regulatory T cells (Treg) capable of preventing and correcting immunopathology. There has been much interest in exploiting Treg as adoptive cell therapy in man, but issues of lack of nominal antigen-specificity and stability of FoxP3 expression in the face of pro-inflammatory cytokines have been a concern. In order to enable fundamental studies of human FOXP3 (hFOXP3) gene regulation and to provide preclinical tools to guide the selection of drugs that might modulate hFOXP3 expression for therapeutic purposes, we generated hFOXP3/AmCyan bacterial artificial chromosome (BAC) transgenic mice and transfectants, wherein hFOXP3 expression was read out as AmCyan expression. Using the transgenic mice, one can now investigate hFOXP3 gene expression under defined experimental conditions used for mouse Foxp3 (mFoxp3) studies. Here, we demonstrate that hFOXP3 gene expression in BAC transgenic mice is solely restricted to CD4+ T-cells, as for mFoxp3 gene expression, showing that hFOXP3 expression in Treg cells depends on fundamentally similar processes to mFoxp3 expression in these cells. Similarly, hFOXP3 expression could be observed in mouse T-cells through TCR stimulation in the presence of TGF-ß. These data suggest that, at least in part, cell type-specific human and mouse foxp3 gene expression is regulated by common regulatory regions which for the human, are located within the 110-kb human FOXP3 BAC DNA. To investigate hFOXP3 gene expression further and to screen potential therapeutics in modulating hFOXP3 gene expression in vitro, we also generated hFOXP3/AmCyan expression reporter cell lines. Using the reporter cells and transcription factor inhibitors, we showed that, just as for mFoxp3 expression, inhibitors of NF-κB, AP1, STAT5, Smad3, and NFAT also block hFOXP3 expression. hFOXP3 induction in the reporter cells was also TGF-ß dependent, and substantially enhanced by an mTOR inhibitor, Torin1. In both the reporter transgenic mice and cell lines, histone H4 molecules in the hFOXP3 promoter and enhancers located in human CNS1 and CNS2 regions were highly acetylated in natural Treg and TCR/TGF-ß-induced Treg, indicating hFOXP3 gene expression is regulated by mechanisms similar to those previously identified for the mFoxp3 gene.
RÉSUMÉ
Cushing's syndrome is caused by excessive adrenocorticotropic hormone (ACTH) secretion derived from pituitary corticotroph tumors (Cushing disease) or from non-pituitary tumors (ectopic Cushing's syndrome). Hypercortisolemic features of ectopic Cushing's syndrome are severe, and no definitive treatment for paraneoplastic ACTH excess is available. We aimed to identify subcellular therapeutic targets by elucidating transcriptional regulation of the human ACTH precursor POMC (proopiomelanocortin) and ACTH production in non-pituitary tumor cells and in cell lines derived from patients with ectopic Cushing's syndrome. We show that ectopic hPOMC transcription proceeds independently of pituitary-specific Tpit/Pitx1 and demonstrate a novel E2F1-mediated transcriptional mechanism regulating hPOMC We identify an E2F1 cluster binding to the proximal hPOMC promoter region (-42 to +68), with DNA-binding activity determined by the phosphorylation at Ser-337. hPOMC mRNA expression in cancer cells was upregulated (up to 40-fold) by the co-expression of E2F1 and its heterodimer partner DP1. Direct and indirect inhibitors of E2F1 activity suppressed hPOMC gene expression and ACTH by modifying E2F1 DNA-binding activity in ectopic Cushing's cell lines and primary tumor cells, and also suppressed paraneoplastic ACTH and cortisol levels in xenografted mice. E2F1-mediated hPOMC transcription is a potential target for suppressing ACTH production in ectopic Cushing's syndrome.
Sujet(s)
Syndrome de sécrétion ectopique d'ACTH/génétique , Tumeur carcinoïde/génétique , Facteur de transcription E2F1/physiologie , Tumeurs du poumon/génétique , Pro-opiomélanocortine/génétique , Adénome à ACTH/génétique , Adénome à ACTH/métabolisme , Adénomes/génétique , Adénomes/métabolisme , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Animaux , Tumeur carcinoïde/métabolisme , Cellules cultivées , Syndrome de Cushing/génétique , Femelle , Régulation de l'expression des gènes tumoraux , Humains , Tumeurs du poumon/métabolisme , Mâle , Souris , Adulte d'âge moyen , Pro-opiomélanocortine/métabolisme , Jeune adulteRÉSUMÉ
CONTEXT: Cushing disease, due to pituitary corticotroph tumor ACTH hypersecretion, drives excess adrenal cortisol production with adverse morbidity and mortality. Loss of glucocorticoid negative feedback on the hypothalamic-pituitary-adrenal axis leads to autonomous transcription of the corticotroph precursor hormone proopiomelanocortin (POMC), consequent ACTH overproduction, and adrenal hypercortisolism. We previously reported that R-roscovitine (CYC202, seliciclib), a 2,6,9-trisubstituted purine analog, suppresses cyclin-dependent-kinase 2/cyclin E and inhibits ACTH in mice and zebrafish. We hypothesized that intrapituitary cyclin E signaling regulates corticotroph tumor POMC transcription independently of cell cycle progression. The aim was to investigate whether R-roscovitine inhibits human ACTH in corticotroph tumors by targeting the cyclin-dependent kinase 2/cyclin E signaling pathway. METHODS: Primary cell cultures of surgically resected human corticotroph tumors were treated with or without R-roscovitine, ACTH measured by RIA and quantitative PCR, and/or Western blot analysis performed to investigate ACTH and lineage-specific transcription factors. Cyclin E and E2F transcription factor 1 (E2F1) small interfering RNA (siRNA) transfection was performed in murine corticotroph tumor AtT20 cells to elucidate mechanisms for drug action. POMC gene promoter activity in response to R-roscovitine treatment was analyzed using luciferase reporter and chromatin immunoprecipitation assays. RESULTS: R-roscovitine inhibits human corticotroph tumor POMC and Tpit/Tbx19 transcription with decreased ACTH expression. Cyclin E and E2F1 exhibit reciprocal positive regulation in corticotroph tumors. R-roscovitine disrupts E2F1 binding to the POMC gene promoter and suppresses Tpit/Tbx19 and other lineage-specific POMC transcription cofactors via E2F1-dependent and -independent pathways. CONCLUSION: R-roscovitine inhibits human pituitary corticotroph tumor ACTH by targeting the cyclin E/E2F1 pathway. Pituitary cyclin E/E2F1 signaling is a previously unappreciated molecular mechanism underlying neuroendocrine regulation of the hypothalamic-pituitary-adrenal axis, providing a subcellular therapeutic target for small molecule cyclin-dependent kinase 2 inhibitors of pituitary ACTH-dependent hypercortisolism, ie, Cushing disease.
Sujet(s)
Antinéoplasiques/usage thérapeutique , Cycline E/antagonistes et inhibiteurs , Thérapie moléculaire ciblée/méthodes , Hypersécrétion hypophysaire d'ACTH/traitement médicamenteux , Pro-opiomélanocortine/génétique , Purines/usage thérapeutique , Adénome à ACTH/complications , Adénome à ACTH/traitement médicamenteux , Adénome à ACTH/génétique , Adénome à ACTH/anatomopathologie , Adénomes/complications , Adénomes/traitement médicamenteux , Adénomes/génétique , Adénomes/anatomopathologie , Adolescent , Adulte , Sujet âgé , Cycline E/physiologie , Femelle , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Humains , Mâle , Hypersécrétion hypophysaire d'ACTH/anatomopathologie , Culture de cellules primaires , Pro-opiomélanocortine/métabolisme , Roscovitine , Cellules cancéreuses en culture , Jeune adulteRÉSUMÉ
As ErbB receptors are expressed in prolactinomas and exhibit downstream effects on prolactin (PRL) production and cell proliferation, we generated transgenic mice using a PRL enhancer/promoter expression system to restrict lactotroph-specific expression of human epidermal growth factor receptor (EGFR) or human EGFR2 (HER2). EGFR or HER2 transgenic mice developed prolactinomas between 13 and 15 months, and confocal immunofluorescence and Western blot analysis confirmed lactotroph-restricted PRL and EGFR or HER2 coexpression. Circulating PRL levels in EGFR and HER2 transgenic mice were increased 5- and 3.8-fold, respectively. Inhibiting EGFR or HER2 signaling with oral lapatinib (100 mg/kg), a dual tyrosine kinase inhibitor for both EGFR and HER2, suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80% and also attenuated downstream tumor EGFR/HER2 signaling. This model demonstrates the role of ErbB receptors underlying prolactinoma tumorigenesis and the feasibility of targeting these receptors for translation to treatment of refractory prolactinomas.
Sujet(s)
Antinéoplasiques/usage thérapeutique , Récepteurs ErbB/métabolisme , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Tumeurs de l'hypophyse/traitement médicamenteux , Prolactinome/traitement médicamenteux , Quinazolines/usage thérapeutique , Animaux , Éléments activateurs (génétique) , Récepteurs ErbB/génétique , Femelle , Régulation de l'expression des gènes tumoraux/physiologie , Humains , Lapatinib , Souris , Souris transgéniques , Tumeurs de l'hypophyse/génétique , Tumeurs de l'hypophyse/métabolisme , Prolactinome/génétique , Prolactinome/métabolisme , Régions promotrices (génétique)RÉSUMÉ
Glucocorticoid-induced TNFR (Gitr) and Ox40, two members of the TNFR superfamily, play important roles in regulating activities of effector and regulatory T cells (Treg). Their gene expression is induced by T cell activation and further upregulated in Foxp3+ Treg. Although the role of Foxp3 as a transcriptional repressor in Treg is well established, the mechanisms underlying Foxp3-mediated transcriptional upregulation remain poorly understood. This transcription factor seems to upregulate expression not only of Gitr and Ox40, but also other genes, including Ctla4, Il35, Cd25, all critical to Treg function. To investigate how Foxp3 achieves such upregulation, we analyzed its activity on Gitr and Ox40 genes located within a 15.1-kb region. We identified an enhancer located downstream of the Gitr gene, and both Gitr and Ox40 promoter activities were shown to be upregulated by the NF-κB-mediated enhancer activity. We also show, using the Gitr promoter, that the enhancer activity was further upregulated in conjunction with Foxp3. Foxp3 appears to stabilize NF-κB p50 binding by anchoring it to the enhancer, thereby enabling local accumulation of transcriptional complexes containing other members of the NF-κB and IκB families. These findings may explain how Foxp3 can activate expression of certain genes while suppressing others.
Sujet(s)
Éléments activateurs (génétique) , Facteurs de transcription Forkhead/métabolisme , Régulation de l'expression des gènes , Locus génétiques , Protéine associée au récepteur du TNF induit par les corticoïdes/génétique , Facteur de transcription NF-kappa B/métabolisme , Animaux , Sites de fixation , Antigènes CD3/métabolisme , Activation des lymphocytes/génétique , Activation des lymphocytes/immunologie , Souris , Liaison aux protéines , Récepteur au OX40/génétique , Éléments de réponse , Sous-populations de lymphocytes T/immunologie , Sous-populations de lymphocytes T/métabolisme , Lymphocytes T régulateurs/immunologie , Lymphocytes T régulateurs/métabolisme , Activation de la transcriptionRÉSUMÉ
Foxp3 plays an important role in the development and the function of regulatory T cells (Treg). Both the induction and maintenance of Foxp3 gene expression are controlled by several regulatory regions including two enhancers in the conserved noncoding sequences (CNS). The functions of Enhancer 1 in CNS1 are well established, whereas those of Enhancer 2 in CNS2 remain unclear. Although CNS2 contains enhancer activity, methylated CpG sequences in this region prevent Foxp3 gene expression in Foxp3(-) T cells. These sequences are, however, demethylated in Foxp3(+) Treg by mechanisms as yet unknown. To investigate the role of CNS2, we have determined the Enhancer 2 core sequence by luciferase reporter assays in the absence of methylation to exclude the inhibitory effect and shown that transcription factors AP-1, Stat5, and Creb cooperate in regulating Enhancer 2 activity. We have then determined the methylation sensitivity of each of the transcription factors. AP-1 was found to be methylation sensitive as has previously been described for Creb. However, Stat5 was active even when its binding site in CNS2 was methylated. Stat5 binding to Enhancer 2 occurred early and preceded that of AP-1 and Creb during Treg induction. In addition, Stat5 activation is itself dependent on TGF-ß signaling through Smad3-mediated blockade of Socs3 expression. These findings suggest that Stat5 is a key regulator for opening up the CNS2 region during induced Treg induction, whereas AP-1 and Creb maintain Enhancer 2 activity.
Sujet(s)
Protéine de liaison à l'élément de réponse à l'AMP cyclique/métabolisme , Éléments activateurs (génétique) , Facteurs de transcription Forkhead/génétique , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Facteur de transcription STAT-5/métabolisme , Facteur de transcription AP-1/métabolisme , Facteur de croissance transformant bêta/pharmacologie , Acétylation , Animaux , Séquence nucléotidique , Sites de fixation , Facteurs de transcription Forkhead/composition chimique , Facteurs de transcription Forkhead/métabolisme , Histone/métabolisme , Souris , Données de séquences moléculaires , Séquences d'acides nucléiques régulatrices , Lymphocytes T régulateurs/métabolismeRÉSUMÉ
Elevated levels of ß-site APP cleaving enzyme 1 (BACE1) were found in the brain of some sporadic Alzheimer's disease (AD) patients; however, the underlying mechanism is unknown. BACE1 cleaves ß-amyloid precursor protein (APP) to generate amyloid ß protein (Aß), a central component of neuritic plaques in AD brains. Nuclear factor-kappa B (NF-κB) signalling plays an important role in gene regulation and is implicated in inflammation, oxidative stress and apoptosis. In this report we found that both BACE1 and NF-κB p65 levels were significantly increased in the brains of AD patients. Two functional NF-κB-binding elements were identified in the human BACE1 promoter region. We found that NF-κB p65 expression resulted in increased BACE1 promoter activity and BACE1 transcription, while disruption of NF-κB p65 decreased BACE1 gene expression in p65 knockout (RelA-knockout) cells. In addition, NF-κB p65 expression leads to up-regulated ß-secretase cleavage and Aß production, while non-steroidal anti-inflammatory drugs (NSAIDs) inhibited BACE1 transcriptional activation induced by strong NF-κB activator tumour necrosis factor-alpha (TNF-α). Taken together, our results clearly demonstrate that NF-κB signalling facilitates BACE1 gene expression and APP processing, and increased BACE1 expression mediated by NF-κB signalling in the brain could be one of the novel molecular mechanisms underlying the development of AD in some sporadic cases. Furthermore, NSAIDs could block the inflammation-induced BACE1 transcription and Aß production. Our study suggests that inhibition of NF-κB-mediated BACE1 expression may be a valuable drug target for AD therapy.
Sujet(s)
Maladie d'Alzheimer/métabolisme , Amyloid precursor protein secretases/métabolisme , Aspartic acid endopeptidases/métabolisme , Encéphale/métabolisme , Facteur de transcription RelA/métabolisme , Sujet âgé , Sujet âgé de 80 ans ou plus , Amyloid precursor protein secretases/génétique , Peptides bêta-amyloïdes/métabolisme , Précurseur de la protéine bêta-amyloïde/métabolisme , Anti-inflammatoires non stéroïdiens/pharmacologie , Aspartic acid endopeptidases/génétique , Humains , Régions promotrices (génétique) , Transduction du signal/effets des médicaments et des substances chimiques , Transcription génétique/effets des médicaments et des substances chimiques , Facteur de nécrose tumorale alpha/métabolisme , Régulation positiveSujet(s)
Facteurs de transcription à motif basique hélice-boucle-hélice/métabolisme , Facteurs de transcription Forkhead/métabolisme , Membre-3 du groupe F de la sous-famille-1 de récepteurs nucléaires/métabolisme , Lymphocytes T régulateurs/métabolisme , Cellules Th17/métabolisme , Animaux , Facteurs de transcription à motif basique hélice-boucle-hélice/immunologie , Différenciation cellulaire , Facteurs de transcription Forkhead/génétique , Facteurs de transcription Forkhead/immunologie , Régulation de l'expression des gènes/immunologie , Réseaux de régulation génique/immunologie , Souris , Souris knockout , Membre-3 du groupe F de la sous-famille-1 de récepteurs nucléaires/génétique , Membre-3 du groupe F de la sous-famille-1 de récepteurs nucléaires/immunologie , Régions promotrices (génétique)/génétique , Liaison aux protéines/génétique , Lymphocytes T régulateurs/immunologie , Lymphocytes T régulateurs/anatomopathologie , Cellules Th17/immunologie , Cellules Th17/anatomopathologie , Facteur de croissance transformant bêta-1/immunologie , Facteur de croissance transformant bêta-1/métabolismeRÉSUMÉ
Adjuvants, including antibodies to tumour necrosis factor receptor superfamily members, augment immune responses. One member of this family, glucocorticoid-induced tumour necrosis factor receptor (GITR), is expressed at low levels on naive/resting T cells, B cells and macrophages, but at higher levels on T regulatory cells. The aim of this study was to determine the ability of a rat anti-mouse GITR monoclonal antibody, 2F8, to stimulate murine humoral and cellular immunity in a prime boost model with particular attention to posology and antigen-specific effects. 2F8 enhanced the humoral immune response to ovalbumin and haemagglutinin (HA) compared with controls and this enhancement was equal to or greater than that obtained in mice dosed with standard adjuvants. 2F8 F(ab')(2) fragments were as effective as intact antibody in boosting humoral immunity, indicating that FcR-mediated cross-linking of 2F8 is not required for efficacy. Moreover, the enhanced response was durable and antigen specific. Administration of 2F8 shifted the immune response towards a T helper type 1 response with significant enhancement of immunoglobulin G2a- and G2b-specific anti-HA antibodies, as well as enhanced cellular immunity as measured by ELISPOT. 2F8-treated mice also generated significantly more neutralizing antibodies to HA than control mice. Our findings show that anti-GITR is a robust, versatile adjuvant that, unlike commonly used adjuvants that primarily enhance humoral immunity, enhances both humoral and cellular immunity. These results support the continued development of anti-GITR for such indications as haematological and solid tumours, chronic viral infections, and as a vaccine adjuvant.
Sujet(s)
Adjuvants immunologiques/pharmacologie , Anticorps monoclonaux/pharmacologie , Lymphocytes B/immunologie , Immunité humorale/effets des médicaments et des substances chimiques , Macrophages/immunologie , Récepteurs facteur croissance nerf/immunologie , Récepteurs aux facteurs de nécrose tumorale/immunologie , Lymphocytes auxiliaires Th1/immunologie , Animaux , Anticorps monoclonaux/immunologie , Protéine associée au récepteur du TNF induit par les corticoïdes , Hémagglutinines/immunologie , Hémagglutinines/pharmacologie , Immunité cellulaire/effets des médicaments et des substances chimiques , Immunité cellulaire/immunologie , Fragments Fab d'immunoglobuline/immunologie , Fragments Fab d'immunoglobuline/pharmacologie , Immunoglobuline G/immunologie , Souris , Souris de lignée BALB C , Ovalbumine/immunologie , Ovalbumine/pharmacologie , RatsRÉSUMÉ
In the aftermath of thymic negative selection, natural and adaptive regulatory T cells (Tregs) must acknowledge peripheral, "danger-free" self-Ag to ensure their sustained activity. In this paper, we show that natural and adaptive Tregs or T cells transduced with cDNA for Foxp3, just like Th1 cells, express members of the MS4A family of transmembrane molecules. Naive T cells transduced with MS4A4B become able to respond to lower levels of Ag. Using two family members, MS4A4B and MS4A6B, as baits in a yeast split-ubiquitin Treg library screen, we demonstrate their interaction with each other and with GITR, Orai1, and other surface receptors. Interaction of 4B with GITR augments GITR signaling and T cell IL-2 production in response to triggering with GITR ligand or anti-GITR Abs. This interaction provides a mechanism whereby MS4A family members, through lateral coassociation with costimulatory molecules, may amplify Ag signals. We propose that T cells preoccupied with immune defense use this MS4A family to enhance sensitivity to extrinsic Ag stimulation, ensuring its elimination, while Tregs use these adaptors to allow low level Ag signals to sustain regulatory function.
Sujet(s)
Protéines adaptatrices de la transduction du signal/biosynthèse , Protéines adaptatrices de la transduction du signal/génétique , Activation des lymphocytes/immunologie , Protéines membranaires/biosynthèse , Protéines membranaires/génétique , Récepteurs facteur croissance nerf/métabolisme , Récepteurs aux facteurs de nécrose tumorale/métabolisme , Lymphocytes T régulateurs/immunologie , Lymphocytes T régulateurs/métabolisme , Protéines adaptatrices de la transduction du signal/physiologie , Séquence d'acides aminés , Animaux , Cellules CHO , Lignée cellulaire , Cricetinae , Cricetulus , Analyse de profil d'expression de gènes , Protéine associée au récepteur du TNF induit par les corticoïdes , Humains , Activation des lymphocytes/génétique , Protéines membranaires/physiologie , Souris , Souris de lignée CBA , Souris knockout , Souris transgéniques , Données de séquences moléculaires , Séquençage par oligonucléotides en batterie , Récepteurs facteur croissance nerf/physiologie , Récepteurs aux facteurs de nécrose tumorale/physiologie , Régulation positive/génétique , Régulation positive/immunologieRÉSUMÉ
Regulatory T (Treg) cells are essential for maintaining immune homeostasis. Although Foxp3 expression marks the commitment of progenitors to Treg cell lineage, how Treg cells are generated during lymphocyte development remains enigmatic. We report here that the c-Rel transcription factor controlled development of Treg cells by promoting the formation of a Foxp3-specific enhanceosome. This enhanceosome contained c-Rel, p65, NFAT, Smad, and CREB. Although Smad and CREB first bound to Foxp3 enhancers, they later moved to the promoter to form the c-Rel enhanceosome. c-Rel-deficient mice had up to 90% reductions of Treg cells compared to wild-type mice, and c-Rel-deficient T cells were compromised in Treg cell differentiation. Thus, Treg cell development is controlled by a c-Rel enhanceosome, and strategies targeting Rel-NF-kappaB can be effective for manipulating Treg cell function.
Sujet(s)
Facteurs de transcription Forkhead/génétique , Régulation de l'expression des gènes , Protéines proto-oncogènes c-rel/génétique , Lymphocytes T régulateurs/immunologie , Facteur de transcription RelA/immunologie , Animaux , Différenciation cellulaire , Protéine de liaison à l'élément de réponse à l'AMP cyclique/métabolisme , Souris , Souris de lignée C57BL , Facteurs de transcription NFATC/métabolisme , Régions promotrices (génétique) , Protéines proto-oncogènes c-rel/métabolisme , Protéines Smad/métabolisme , Facteur de transcription RelA/métabolismeRÉSUMÉ
Glucocorticoid-induced TNF receptor ligand (GITRL) is a member of the TNF super family (TNFSF). GITRL plays an important role in controlling regulatory T cells. The crystal structure of the mouse GITRL (mGITRL) was determined to 1.8-A resolution. Contrary to the current paradigm that all ligands in the TNFSF are trimeric, mGITRL associates as dimer through a unique C terminus tethering arm. Analytical ultracentrifuge studies revealed that in solution, the recombinant mGITRL exists as monomers at low concentrations and as dimers at high concentrations. Biochemical studies confirmed that the mGITRL dimer is biologically active. Removal of the three terminal residues in the C terminus resulted in enhanced receptor-mediated NF-kappaB activation than by the wild-type receptor complex. However, deletion of the tethering C-terminus arm led to reduced activity. Our studies suggest that the mGITRL may undergo a dynamic population shift among different oligomeric forms via C terminus-mediated conformational changes. We hypothesize that specific oligomeric forms of GITRL may be used as a means to differentially control GITR receptor signaling in diverse cells.
Sujet(s)
Récepteurs facteur croissance nerf/physiologie , Récepteurs aux facteurs de nécrose tumorale/physiologie , Animaux , Cellules COS , Chlorocebus aethiops , Cristallographie aux rayons X/méthodes , Dimérisation , Protéine associée au récepteur du TNF induit par les corticoïdes , Ligands , Souris , Modèles biologiques , Modèles moléculaires , Conformation moléculaire , Facteur de transcription NF-kappa B/métabolisme , Conformation des protéines , Structure tertiaire des protéines , Récepteurs facteur croissance nerf/composition chimique , Récepteurs aux facteurs de nécrose tumorale/composition chimique , Lymphocytes T/métabolisme , Facteurs de nécrose tumorale/métabolismeRÉSUMÉ
The transcription factor Foxp3 is involved in the differentiation, function and survival of CD4+CD25+ regulatory T (T(reg)) cells. Details of the mechanism underlying the induction of Foxp3 expression remain unknown, because studies of the transcriptional regulation of the Foxp3 gene are limited by the small number of T(reg) cells in mononuclear cell populations. Here we have generated a model system for analyzing Foxp3 induction and, by using this system with primary T cells, we have identified an enhancer element in this gene. The transcription factors Smad3 and NFAT are required for activity of this Foxp3 enhancer, and both factors are essential for histone acetylation in the enhancer region and induction of Foxp3. These biochemical properties that define Foxp3 expression explain many of the effects of transforming growth factor-beta on the function of Foxp3+ T(reg) cells.
Sujet(s)
Éléments activateurs (génétique) , Facteurs de transcription Forkhead/génétique , Régulation de l'expression des gènes , Facteurs de transcription NFATC/métabolisme , Protéine Smad-3/métabolisme , Lymphocytes T régulateurs/immunologie , Animaux , Séquence nucléotidique , Lignée cellulaire tumorale , Souris , Données de séquences moléculairesRÉSUMÉ
OX40 is a member of the TNFR superfamily (CD134; TNFRSF4) that is expressed on activated T cells and regulates T cell-mediated immune responses. In this study, we have examined the regulation of OX40 gene expression in T cells. Low-level OX40 mRNA expression was detected in both resting T cells and the nonactivated EL4 T cell line, and was up-regulated in both types of T cells upon activation with anti-CD3 Ab. We have shown in this study that basal OX40 promoter activity is regulated by constitutively expressed Sp1/Sp3 and YY1 transcription factors. NF-kappaB (p50 and p65) also binds to the OX40 promoter region, but the level of direct enhancement of the OX40 promoter activity by this transcription factor is not sufficient to account for the observed up-regulation of OX40 mRNA expression associated with activation. We have detected by chromatin immunoprecipitation that histone H4 molecules in the OX40 promoter region are highly acetylated by activation and NF-kappaB binds to the OX40 promoter in vivo. These findings suggest that OX40 gene expression is regulated by chromatin remodeling, and that NF-kappaB might be involved in initiation of chromatin remodeling in the OX40 promoter region in activated T cells. CD4(+)CD25(+) regulatory T (Treg) cells also express OX40 at high levels, and signaling through this receptor can neutralize suppressive activity of this Treg cell. In CD4(+)CD25(+) Treg cells, histone H4 molecules in the OX40 promoter region are also highly acetylated, even in the absence of in vitro activation.
Sujet(s)
Assemblage et désassemblage de la chromatine/immunologie , Sous-unité p50 de NF-kappa B/métabolisme , Régions promotrices (génétique)/immunologie , Récepteur au OX40/génétique , Facteur de transcription Sp1/métabolisme , Facteur de transcription Sp3/métabolisme , Régulation positive/immunologie , Facteur de transcription YY1/métabolisme , Animaux , Sites de fixation/génétique , Sites de fixation/immunologie , Antigènes CD3/immunologie , Lignée cellulaire tumorale , Assemblage et désassemblage de la chromatine/génétique , Sérums immuns/pharmacologie , Activation des lymphocytes/génétique , Activation des lymphocytes/immunologie , Lymphome T/génétique , Lymphome T/immunologie , Lymphome T/métabolisme , Souris , ARN messager/biosynthèse , Récepteur au OX40/biosynthèse , Récepteur au OX40/métabolisme , Facteur de transcription Sp1/physiologie , Facteur de transcription Sp3/physiologie , Lymphocytes T/immunologie , Lymphocytes T/métabolisme , Facteur de transcription RelA/métabolisme , Régulation positive/génétique , Facteur de transcription YY1/physiologieRÉSUMÉ
Adenosine receptor ligands have anti-inflammatory effects and modulate immune responses by up-regulating IL-10 production by immunostimulated macrophages. The adenosine receptor family comprises G protein-coupled heptahelical transmembrane receptors classified into four types: A1, A2A, A2B, and A3. Our understanding of the signaling mechanisms leading to enhanced IL-10 production following adenosine receptor occupancy on macrophages is limited. In this study, we demonstrate that adenosine receptor occupancy increases IL-10 production by LPS-stimulated macrophages without affecting IL-10 promoter activity and IL-10 mRNA levels, indicating a posttranscriptional mechanism. Transfection experiments with reporter constructs containing sequences corresponding to the AU-rich 3'-untranslated region (UTR) of IL-10 mRNA confirmed that adenosine receptor activation acts by relieving the translational repressive effect of the IL-10 3'-UTR. By contrast, adenosine receptor activation failed to liberate the translational arrest conferred by the 3'-UTR of TNF-alpha mRNA. The IL-10 3'-UTR formed specific complexes with proteins present in cytoplasmic extracts of RAW 264.7 cells. Adenosine enhanced binding of proteins to a region of the IL-10 3'-UTR containing the GUAUUUAUU nonamer. The stimulatory effect of adenosine on IL-10 production was mediated through the A(2B) receptor, because the order of potency of selective agonists was 5'-N-ethylcarboxamidoadenosine (NECA) > N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA) > 2-chloro-N6-cyclopentyladenosine (CCPA) = 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethyl-carboxamidoadenosine (CGS-21680). Also, the selective A2B antagonist, alloxazine, prevented the effect of adenosine. Collectively, these studies identify a novel pathway in which activation of a G protein-coupled receptor augments translation of an anti-inflammatory gene.
Sujet(s)
Adénosine/physiologie , Régulation de l'expression des gènes/immunologie , Interleukine-10/biosynthèse , Macrophages/métabolisme , Biosynthèse des protéines , Récepteur A2B à l'adénosine/physiologie , Régions 3' non traduites , Agonistes des récepteurs A2 à l'adénosine , Animaux , Lignée cellulaire , Ligands , Lipopolysaccharides/pharmacologie , Souris , Régions promotrices (génétique) , ARN messager/analyseRÉSUMÉ
This report evaluates the role of interaction between glucocorticoid-induced tumor necrosis factor receptor (GITR) and GITR ligand (GITR-L) in the immuno-inflammatory response to infection with herpes simplex virus (HSV). Both GITR and GITR-L were transiently upregulated after ocular HSV infection, on antigen-specific T cells and antigen-presenting cells, respectively, in the draining lymph node (DLN). In addition, virus-specific T-cell responses in the DLN and spleen were enhanced by anti-GITR antibody treatment, an outcome expected to result in more severe inflammatory lesions. Intriguingly, the treatment resulted in significantly diminished T-cell-mediated ocular lesions. The explanation for these findings was that anti-GITR antibody treatment caused a reduced production of ocular MMP-9, a molecule involved in ocular angiogenesis, an essential step in the pathogenesis of herpetic keratitis. Our results are the first observations to determine in vivo kinetics of GITR and GITR-L expression after virus infection, and they emphasize the role of GITR-GITR-L interaction to regulate virus-induced immuno-inflammatory lesions.
Sujet(s)
Protéines de transport/physiologie , Herpèsvirus humain de type 1/immunologie , Récepteurs facteur croissance nerf/physiologie , Récepteurs aux facteurs de nécrose tumorale/physiologie , Animaux , Anticorps monoclonaux/administration et posologie , Cellules présentatrices d'antigène/immunologie , Lymphocytes T CD4+/immunologie , Lymphocytes T CD8+/immunologie , Protéines de transport/génétique , Femelle , Protéine associée au récepteur du TNF induit par les corticoïdes , Herpèsvirus humain de type 1/physiologie , Kératite herpétique/immunologie , Kératite herpétique/anatomopathologie , Kératite herpétique/virologie , Cinétique , Matrix metalloproteinase 9/biosynthèse , Souris , Souris congéniques , Souris de lignée C57BL , Récepteurs facteur croissance nerf/antagonistes et inhibiteurs , Récepteurs facteur croissance nerf/génétique , Récepteurs facteur croissance nerf/immunologie , Récepteurs aux facteurs de nécrose tumorale/antagonistes et inhibiteurs , Récepteurs aux facteurs de nécrose tumorale/génétique , Récepteurs aux facteurs de nécrose tumorale/immunologie , Facteurs de nécrose tumorale , Régulation positiveRÉSUMÉ
Dendritic cells (DC) are professional APCs that play a critical role in regulating immunity. In DC, maturation-induced changes in MHC class II expression and Ag presentation require transcriptional regulation by CIITA. To study the role of CIITA in DC, we evaluated key cell functions in DC from CIITA-deficient (CIITA(-/-)) mice. The ability to take up Ag, measured by fluid phase endocytosis, was comparable between CIITA(-/-) and control DC. Although CIITA(-/-) DC lack MHC class II, they maintained normal expression of costimulatory molecules CD80, CD86, and CD40. In contrast, CIITA(-/-) DC activated with LPS or CpG expressed increased IL-10 levels, but normal levels of TNF-alpha and IL-12 relative to control. Enhanced IL-10 was due to greater IL-10 mRNA in CIITA(-/-) DC. Abeta(-/-) DC, which lack MHC class II but express CIITA normally, had exhibited no difference in IL-10 compared with control. When CIITA was cotransfected with an IL-10 promoter-reporter into a mouse monocyte cell line, RAW 264.7, IL-10 promoter activity was decreased. In addition, reintroducing CIITA into CIITA(-/-) DC reduced production of IL-10. In all, these data suggest that CIITA negatively regulates expression of IL-10, and that CIITA may direct DC function in ways that extend beyond control of MHC class II.